You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Early Warning system for detecting pre-eclampsia
SBC: CONVERGENT ENGINEERING INC Topic: NICHDDESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Body Worn EMG Controlling of Assistive Robotic Arm for Stroke Rehabilitation
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: NINDSDESCRIPTION (provided by applicant): Stroke is the leading cause of adult disability and the third leading cause of death in the United States. Approximately 15 million people in the world, and more than 700,000 people in the United States, experience a stroke each year. Following a hemispheric stroke, motor control of extremities on one side of the body is usually affected. Many patients suffer a ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity
SBC: INVENUX, LLC Topic: NCCAMDESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis
SBC: Stemsynergy Therapeutic Topic: 102DESCRIPTION provided by applicant The tumor suppressor Adenomatous Polyposis Coli APC directs degradation of catenin a central signaling protein in the WNT pathway Germline loss of function mutations in APC activate WNT signaling and underlie the inherited colorectal cancer predisposition syndrome Familial Adenomatous Polyposis FAP an orphan disease while somatic mutations lead to spo ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Novel Assay System and Analysis Algorithm in Detecting RNA Editing Events and Linked Splicing Isoforms
SBC: Celetrix LLC Topic: NIDAAbstract RNA editing is a process in which the genome encoded information is altered in RNA RNA editing is an efficient way to increase RNA complexity thereby fine tuning both gene function and dosage Adenosine to Inosine A to I editing is the most common type of RNA editing known in animals The cellular machinery recognizes inosine as guanosine so A to I editing of codons and splicing sign ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A cloud-based secure patient information exchange framework for managing treatment accessibility, utilization, quality, and outcomes in behavioral health clinics
SBC: Waldron International llc Topic: NIDADESCRIPTION In communities across the United States clinical populations exhibiting mental health and or substance abuse disorders face substantial challenges in accessing and receiving high quality and effective behavioral healthcare services Health Information technology HIT has been identified as an important component of improving access to behavioral healthcare in rural communities yet t ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
High-potency nitro antimicrobials for topical treatment of trichomoniasis
SBC: DESIGNMEDIX, INC. Topic: RDESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
development of immunodeficient rabbit models
SBC: Celetrix LLC Topic: NIAIDDESCRIPTION provided by applicant Transplantation of human or animal pluripotent stem cells PSCs or their derivatives to model animals constitutes an important preclinical system to model and investigate cell survival development and differentiation in vivo and to assess the safety and efficacy of transplantation based cell therapies Immunodeficient mice are dominantly used in biomedical ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health